Press Release

October 28, 2026 The Manager Listing Department, The National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 Dear Sir/ Madam, Trading Symbol: ZOTA Sub: Press Release titled “Zota Health Care Limited Reports Healthy Q2FY27 Performance, Amid Planned Moderation in Store Expansion.” With reference to the captioned subject; we, M/s Zota Health Care Limited, are forwarding herewith enclosed a copy of press release on Unaudited Financial Results for the quarter and half ended September 30, 2026. This is for your information and record. Thanking you, Yours faithfully, For Zota Health Care Limited Ashvin Variya (Group Company Secretary & Compliance Officer) Place: Surat Encl.: Press Release Registered Office: Zota House, 2/896, Hira Modi Street, Sagrampura, Surat-395002 Ph: +91 261 2331601 Email: info@zotahealthcare.com Web: www.zotahealthcare.com CIN: L24231GJ2000PLC038352 Press Release – Q2FY22 PRESS RELEASE Q2FY27 Zota Health Care Limited Reports Healthy Q2FY27 Performance, Amid Planned Moderation in Store Expansion Consolidated Revenues from operations Grew by 54.58% YoY, EBITDA Stood Positive at ₹791.72 lakhs Davaindia Network Reaches 2,840 Stores Nationwide Surat, October 28, 2026: Zota Health Care Limited, one of the leading pharmaceutical company with an aim is to provide affordable, high-quality, generic medicines predominantly for chronic conditions, in addition to proprietary medicinal, OTC, ayurvedic, cosmetic, and nutraceutical products, announced financial results for the second quarter and half year ended 30th September 2026. Q2FY27 Consolidated Financial Snapshot Quarter Ended Year ended Particulars (₹in Lakhs) Q2FY27 Q1FY27 Q2FY26 H1FY27 H1FY26 Export Sales (SEZ) 470.09 573.51 1,094.98 1,043.60 1,759.06 Davaindia Sales 16,846.81 14,342.33 9,558.59 31,189.14 17,121.49 Domestic Sales 2,459.13 1,790.67 1,790.50 4,249.80 3,297.37 Everyday Herbal Group 806.79 649.42 450.75 1,456.21 1,075.16 Others 21.81 4.30 - 26.11 - Inter-segment Eliminations* -671.49 - - -671.49 - Revenue from Operations 19,933.14 17,360.23 12,894.82 37,293.37 23,253.08 Gross Profit 11,994.05 10,756.00 7,650.26 22,750.04 13,495.25 Gross Margin % 60.17% 61.96% 59.33% 61.00% 58.04% EBITDA 791.72 -955.40 795.71 -163.68 1,278.98 EBITDA Margin% 3.97% -5.50% 6.17% -0.44% 5.50% As on 30th September 2026 (*1. Elimination of common transactions are pertaining to the sales made by M/s Everyday Herbal Beauty Care Ltd. subsidiary of the Company to the parent company's vertical i.e. Davaindia.) Q2FY27 Operational Metrics Snapshot Q2FY27 Q2FY26 Particulars COCO FOFO Total COCO FOFO Total Total No. of Davaindia stores* 1,859 981 2,840 1,207 848 2,055 Quarterly Footfall (₹ lakhs) 48.67 17.50 66.17 29.62 13.91 43.53 Quarterly GMV (₹ lakhs) ₹13,787 ₹5,004 ₹18,791 ₹6,780 ₹3,923 ₹10,598 Average wallets spend (₹) ₹283 ₹286 ₹229 ₹282 As on 30th September 2026 Key Business Highlights: • Davaindia Sales stood at ₹16,846.81 lakhs in Q2FY27, registering a strong 76.25% YoY growth compared with ₹9,558.59 lakhs in Q2FY26. Everyday Herbal Group delivered 78.99% YoY growth, with Q2FY27 sales reaching ₹806.79 lakhs • Profitability witnessed a strong sequential recovery, with EBITDA turning positive at ₹791.72 lakhs, with an EBITDA margin of 3.97%. ZOTA HEALTHCARE LIMITED | WWW.ZOTAHEALTHCARE.COM | Q2FY27 RELEASE | PAGE 1 OF 2 Press Release – Q2FY22 PRESS RELEASE Q2FY27 • Added 20 new stores during Q2FY27 with 4 COCO & 16 FOFO stores. • Closed 5 FOFO stores during Q2FY27. • Converted ₹119.52 crore of outstanding unsecured loan and accumulated interest receivable from wholly owned subsidiary Davaindia Health Mart Limited (DHML) into equity. Against the outstanding amount, 2,35,512 equity shares were allotted at ₹5,075 per share on a preferential basis, with no fresh cash outflow involved in the transaction. Commenting on the Q2FY26 performance, Mr. Ketan Kumar Zota, Chairman, Zota Health Care Limited said, “We are pleased with our performance during Q2FY27, as we continued to strengthen the underlying fundamentals of the business. Revenue from Operations grew by 54.58% YoY, supported by a 76.25% YoY increase in Davaindia Sales and 78.99% YoY growth in Everyday Herbal Group. Importantly, EBITDA turned positive at ₹791.72 lakhs, with an EBITDA margin of 3.97%, marking a significant sequential turnaround in profitability. As communicated during the previous quarter, we consciously moderated the pace of Davaindia store additions during Q2FY27 following the significant expansion undertaken over the past several quarters. During the quarter, our efforts were directed towards consolidating the expanded store network, closely monitoring the performance of recently added stores, improving store-level productivity and strengthening execution across the existing network. This measured approach enabled us to sharpen our focus on the operating performance and cash-generation profile of the expanding store base. Despite moderated store additions, operating momentum remained healthy, with the Davaindia network reaching 2,840 stores, quarterly customer footfalls of 66.17 lakh and GMV of ₹18,791 lakhs. Going forward, our focus remains on sustainable and disciplined growth. Following the measured pace of expansion during Q2FY27, we intend to accelerate Davaindia network additions during H2FY27 and progress towards our full- year expansion plans, while maintaining a strong focus on store-level productivity, operating efficiency and cash generation.” About Zota Health Care Limited: Zota Health Care Ltd. (Zota), listed on the NSE, has been a key player in the Indian healthcare industry since 2000. Headquartered in Surat, Zota's team of over 635 professionals drives its growth and strong market presence. The company specializes in the development, manufacturing, and marketing of high-quality pharmaceutical, ayurvedic, nutraceutical, and over-the-counter products. Zota operates through three main divisions: marketing, export, and the retail pharmacy chain. In 2017, Zota launched Davaindia, a generic pharmacy chain offering over 2,000 SKUs of quality medicines. Davaindia's strategic business model ensures efficient management of the entire product life cycle through backward and forward integration. Zota is renowned for its innovative Research and Development team, consistently investing in pioneering healthcare solutions, reinforcing its reputation in the industry. For more information, visit: www.zotahealthcare.com For details please contact: Ashvin Variya Siddesh Chawan Ajit Mishra Group Company Secretary & Compliance Officer Ernst & Young LLP, Ernst & Young LLP, Zota Health Care Ltd Investor Relations Investor Relations E: cszota@zotahealthcare.com E: Siddesh.Chawan@in.ey.com E: Ajit.J.Mishra@in.ey.com Disclaimer: Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Zota Health Care Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. ZOTA HEALTHCARE LIMITED | WWW.ZOTAHEALTHCARE.COM | Q2FY27 RELEASE | PAGE 2 OF 2